Literature DB >> 1324910

Interleukin-6 signal transducer gp130 mediates oncostatin M signaling.

J Liu1, B Modrell, A Aruffo, J S Marken, T Taga, K Yasukawa, M Murakami, T Kishimoto, M Shoyab.   

Abstract

Oncostatin M (OM) is a multifunctional cytokine that is structurally and functionally related to interleukin 6 (IL-6) and leukemia inhibitory factor (LIF). The specific receptor for OM has been demonstrated (by chemical cross-linking) to be a 150-kDa protein in a number of cell lines. The IL-6 signal transducer, gp130, is also an affinity converter for the LIF receptor. It does not bind to either IL-6 or LIF, but associates with the alpha subunits of the receptors and transduces the signals. We examined the possible involvement of gp130 in OM binding and signaling. We demonstrate that: (a) anti-gp130 monoclonal antibodies (mAbs) block the inhibitory effect of OM on A375 cell growth, (b) the binding and cross-linking of 125I-OM to H2981 cells are completely abolished by anti-gp130 mAbs, (c) the cross-linked OM-receptor complex is immunoprecipitated by anti-gp130 mAbs, and (d) COS-7 cells transfected with the full-length cDNA encoding gp130 exhibit increased OM binding and cross-linking, which are also blocked by anti-gp130 mAbs. Therefore, we conclude that the 150-kDa OM binding protein previously characterized in a variety of cell lines is gp130. OM is the natural ligand for gp130 and gp130 mediates the biological responses of OM.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1324910

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

1.  Functional inhibition of hematopoietic and neurotrophic cytokines by blocking the interleukin 6 signal transducer gp130.

Authors:  T Taga; M Narazaki; K Yasukawa; T Saito; D Miki; M Hamaguchi; S Davis; M Shoyab; G D Yancopoulos; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

2.  Fetal liver development requires a paracrine action of oncostatin M through the gp130 signal transducer.

Authors:  A Kamiya; T Kinoshita; Y Ito; T Matsui; Y Morikawa; E Senba; K Nakashima; T Taga; K Yoshida; T Kishimoto; A Miyajima
Journal:  EMBO J       Date:  1999-04-15       Impact factor: 11.598

3.  Definition and characterization of an inhibitor for interleukin-31.

Authors:  Emilie Venereau; Caroline Diveu; Linda Grimaud; Elisa Ravon; Josy Froger; Laurence Preisser; Yannic Danger; Mike Maillasson; Laure Garrigue-Antar; Yannick Jacques; Sylvie Chevalier; Hugues Gascan
Journal:  J Biol Chem       Date:  2010-03-24       Impact factor: 5.157

4.  Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules.

Authors:  V Modur; M J Feldhaus; A S Weyrich; D L Jicha; S M Prescott; G A Zimmerman; T M McIntyre
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

5.  A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease.

Authors:  K Mitsuyama; N Tomiyasu; A Suzuki; K Takaki; H Takedatsu; J Masuda; H Yamasaki; S Matsumoto; O Tsuruta; A Toyonaga; M Sata
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

6.  Crystal structure of a cytokine-binding region of gp130.

Authors:  J Bravo; D Staunton; J K Heath; E Y Jones
Journal:  EMBO J       Date:  1998-03-16       Impact factor: 11.598

7.  Butyltin compounds alter secretion of interleukin 6 from human immune cells.

Authors:  Shyretha Brown; Wendy Wilburn; Tyesha Martin; Margaret Whalen
Journal:  J Appl Toxicol       Date:  2017-08-24       Impact factor: 3.446

8.  Oncostatin-M stimulates tyrosine protein phosphorylation in parallel with the activation of p42MAPK/ERK-2 in Kaposi's cells. Evidence that this pathway is important in Kaposi cell growth.

Authors:  M C Amaral; S Miles; G Kumar; A E Nel
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

9.  Proliferative responses and binding properties of hematopoietic cells transfected with low-affinity receptors for leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor.

Authors:  D P Gearing; S F Ziegler; M R Comeau; D Friend; B Thoma; D Cosman; L Park; B Mosley
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

Review 10.  The varying faces of IL-6: From cardiac protection to cardiac failure.

Authors:  Jillian A Fontes; Noel R Rose; Daniela Čiháková
Journal:  Cytokine       Date:  2015-01-31       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.